Organic Chemical
Mallinckrodt and Endo Announce $6.7 Billion Merger to Create Diversified Pharmaceutical Leader
Pharmaceutical merger, Mallinckrodt, Endo, opioid litigation, generics, branded drugs, synergies
Gilead hops straight to Phase III with once-yearly HIV PrEP shot
PREP gene, formulations, once-yearly, Trial Phase
FDA’s medical review departments remain largely untouched (for now) by Musk-led cuts
FDA, medical review, drug approval, device regulation, staff cuts, Elon Musk, DOGE, government efficiency
Sotyktu Shows Promise in Phase 3 Psoriatic Arthritis Trial
Sotyktu, deucravacitinib, psoriatic arthritis, Bristol Myers Squibb, POETYK PsA-2 trial, TYK2 inhibitor
AAD25: Ahead of CSU filing, Novartis’ BTK inhibitor shows sleep benefits
Chronic Spontaneous Urticaria, remibrutinib, Sleep, CSU, Novartis
Patent Dispute Erupts Over Merck’s Injectable Keytruda
Merck, Halozyme, Keytruda, patent dispute, injectable cancer drug, enzyme technology
ITM Reports Positive Phase 3 Data for Radiopharmaceutical ITM-11 in Neuroendocrine Tumors, Challenging Novartis’ Lutathera
ITM-11, radiopharmaceutical, Phase 3 COMPETE trial, neuroendocrine tumors, Lutathera, Novartis
FDA Issues Untitled Letter to NJ Drugmaker for Misleading Cancer Drug Claims at Conference
FDA, untitled letter, misleading promotion, exhibit booth, cancer drug, Edenbridge Pharmaceuticals
Novartis Licenses Kyorin’s Preclinical Chronic Hives Drug for $55M Upfront
Novartis, Kyorin Pharmaceutical, KRP-M223, chronic spontaneous urticaria, licensing deal, MRGPRX2 antagonist
Novartis Secures Global Rights to Kyorin’s KRP-M223 for Allergic and Inflammatory Diseases
Novartis, Kyorin Pharmaceutical, KRP-M223, MRGPRX2 antagonist, chronic spontaneous urticaria, Dupixent, licensing agreement